# Clarity AD CSF Substudy Findings on Lecanemab Treatment and α-Synuclein Co-Pathology Presented at CTAD 2026

- Source: PR Newswire M&A
- Published: 2026-11-19T18:35:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/clarity-ad-csf-substudy-findings-on-lecanemab-treatment-and--synuclein-co-pathology-presented-at-ctad-2026-302945650.html
- Canonical: https://groundlevelnews.com/story/clarity-ad-csf-substudy-findings-on-lecanemab-treatment-and-synuclein--a5d07e/

Lecanemab showed favorable results on clinical assessment scores at 18 months, including among individuals with early Alzheimer's disease (AD) who were α-synuclein positive, a subgroup associated with higher amyloid burden and faster clinical decline TOKYO and CAMBRIDGE, Mass., Nov. 19,...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._
